Kurs & Likviditet
|Lista||Mid Cap Stockholm|
|2019-12-17||Extra Bolagsstämma 2019|
|2019-05-22||Ordinarie utdelning ONCO 0.00 SEK|
|2018-05-18||Ordinarie utdelning ONCO 0.00 SEK|
Stockholm - May 15, 2019 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that data from its Phase 1/2 O-12-M1 study evaluating melflufen, a lipophilic peptide-conjugated alkylator belonging to the novel class of peptidase enhanced cytotoxics, in the treatment of relapsed/refractory multiple myeloma (RRMM) have been selected for poster presentation at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31 - June 4 in Chicago.
The data offers an analysis of time to next treatment (TTNT) in patients with RRMM who were treated with melflufen and dexamethasone in the Phase 1/2 clinical study named O-12-M1. TTNT is used in Real World Evidence to assist treatment decisions and support economic reimbursement modeling.
"The acceptance of melflufen data for presentation on the global stage that the ASCO Annual Meeting affords serves as a positive and meaningful validation of the scientific rigor behind our melflufen clinical development program. The early-stage clinical data being presented offer insights into the potential clinical application and utilization of melflufen, which is also being studied now in the global, Phase 3 OCEAN trial" said Jakob Lindberg, CEO of Oncopeptides.
The full 2019 ASCO Annual Meeting abstract book can be found at: https://meetings.asco.org/am/abstracts
The abstract can be found on the company webpage under:
www.oncopeptides.com (https://www.oncopeptides.se/sv/) / Investors & Media / Presentations / Abstract ASCO
Analysis of time to next treatment (TTNT) in melflufen and dexamethasone-treated patients (pts) with relapsed/refractory multiple myeloma (RRMM).
Presenter: Paul G. Richardson, MD, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
Session: Hematologic Malignancies-Plasma Cell Dyscrasia
Date/Time: Monday, June 3, 8:00-11:00 a.m. Central
Location: Hall A (Poster #369)
Abstract number 8043
For further information, please contact:
Jakob Lindberg, CEO of Oncopeptides
Telephone: +46 (0)8 615 20 40
Rein Piir, Head of Investor Relations at Oncopeptides
Cell phone: +46 (0)70 853 72 92
This information was submitted for publication at 23.00 CET, May 15, 2019.
Melflufen is a lipophilic peptide-conjugated alkylator that rapidly delivers a highly cytotoxic payload into myeloma cells through peptidase activity. It belongs to the novel class Peptidase Enhanced Cytotoxics (PEnC), which is a family of lipophilic peptides that exhibit increased activity via peptidase cleavage and have the potential to treat many cancers. Peptidases play a key role in protein homeostasis and feature in cellular processes such as cell-cycle progression and programmed cell death. Melflufen is rapidly taken up by myeloma cells due to its high lipophilicity and is immediately cleaved by peptidases to deliver an entrapped hydrophilic alkylator payload. In vitro, melflufen is 50-fold more potent in myeloma cells than the alkylator payload itself due to the peptidase cleavage, and induces irreversible DNA damage and apoptosis. Melflufen displays cytotoxic activity against myeloma cell lines resistant to other treatments, including alkylators, and has also demonstrated inhibition of DNA repair induction and angiogenesis in preclinical studies.
Oncopeptides is a pharmaceutical company developing drugs for the treatment of cancer. The company is focusing on the development of the lead product candidate melflufen, a novel lipophilic peptide-conjugated alkylator, belonging to a new class of drugs called Peptidase Enhanced Cytotoxics (PEnC). Melflufen is in development as a new treatment for the hematological cancer multiple myeloma and is currently being tested in a global pivotal Phase 3 trial and in three additional supporting clinical trials. Oncopeptides' headquarters is located in Stockholm, Sweden and the company is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO.
Visit www.oncopeptides.com for more information.